Applications


QIAGEN launches first FDA-cleared JAK2 test for certain type of leukemia

New biomarker test – the fifth QIAGEN oncology test with FDA clearance in the U.S. – designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer Germantown, Maryland, and Hilden, Germany, March 29, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ… Read article →


Pyrosequencing for MGMT promoter methylation analysis validated for use in clinical practice

Pyrosequencing is reported as the ideal method for MGMT methylation analysis, and is validated for use in clinical practice. Methylation of the O6-methylguanine- DNA-methyltranferase (MGMT) promoter region is associated with several cancer types, including colorectal cancer, lung cancer, lymphoma and glioblastoma. MGMT promoter methylation is a powerful predictive biomarker of positive response to temozolomide, a… Read article →


QIAGEN launches unique CALR mutation assay for MPN diagnosis

European launch of the new CE marked ipsogen CALR RGQ PCR Kit to improve MPN diagnosis for leukemia patients in line with latest WHO recommendations and clinical guidelines HILDEN, Germany, Dec. 1, 2016 – QIAGEN today announced the European launch of a unique CE-IVD marked calreticulin (CALR) mutation assay to aid in establishing the diagnosis… Read article →


The Prognostic Significance of Gene Mutations in Myeloproliferative Neoplasms

Relevant gene mutations in MPN and their prognostic significance for primary myelofibrosis (PMF). Myeloproliferative neoplasms (MPN) are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. MPN include (primary) myelofibrosis (PMF), essential thrombocythemia (ET) and polycythemia vera (PV), and affect around 13,000, 134,000 and 148,000 patients… Read article →


WT1 expression and NPM1 mutations as biomarkers for minimal residual disease (MRD) monitoring in AML patients

The AML Global Portal highlights the value of AML biomarkers WT1 expression and NPM1 mutation for MRD monitoring in AML patients The AML_Global_Portal is an evidence-based online resource committed to informing and educating health care providers about the latest cutting-edge advancements in acute myeloid leukemia (AML). The portal aims to help advance understanding and share… Read article →


Improved research and diagnostics could help reduce the economic burden of blood disorders

Since the arrival of personalized healthcare and molecular diagnostics, there has been growing support for utilizing DNA, RNA, and protein-based biomarker detection methods as a means to help reduce rising healthcare costs (1). Molecular diagnostics can help select the right patients for the right treatments, and define which patients require costly confirmatory diagnostic tests. In… Read article →


QIAGEN’s companion diagnostic business highlighted in the Journal of Precision Medicine

A recent publication in the Journal of Precision Medicine highlights QIAGEN’s companion diagnostic business development and Modaplex platform. The July 2016 issue of the Journal_of_Precision_Medicine (JPM) features an article by Jessica Johnson called “Companion Diagnostics – a Burgeoning Market” (1). In this article, Johnson provides a brief account of the recent history of companion diagnostics… Read article →


ESMO guidelines committee update clinical recommendations for metastatic colorectal cancer

The European Society for Medical Oncology (ESMO ) is a leading European professional organization for medical oncology and is considered the reference society for oncology education and information. Comprised of more than 13,000 oncology professionals from over 130 countries, ESMO is a home for all oncology stakeholders, and connects professionals with diverse expertise and experience…. Read article →


New study suggests RT-PCR-based ALK assay useful in clinical practice

Anaplastic lymphoma kinase (ALK) gene rearrangements are found in 3–5% of lung adenocarcinomas (ADC) (2–4, Figure 1), and over 20 ALK fusion partners have been implicated in non-small-cell lung cancer (NSCLC) (5). Thanks to the relatively recent development of small molecule targeted therapies, the ALK oncogene is now targetable using ALK tyrosine kinase inhibitors (TKIs)… Read article →


Growing evidence that MET inhibition could treat NSCLC

Evidence continues to grow for the potential therapeutic benefit of mesenchymal-epithelial transition factor proto-oncogene (MET) inhibition to treat non-small cell lung cancer (NSCLC). A recent study by Tong et al. (1) published this past June on MET DNA alterations in NSCLC provides further evidence of the critical role of aberrant MET signaling in the pathogenesis… Read article →